Resistance to ceftriaxone and other beta-lactams in bacteria isolated in the community. The Vigil'Roc Study Group.

Antimicrobial Agents and Chemotherapy
F W GoldsteinJ Gertner

Abstract

The incidence of bacterial species and their susceptibilities to ceftriaxone and other beta-lactams from patients with community-acquired infections were evaluated in a multicenter study over a 4-month period. A total of 5,768 bacterial isolates were classified according to whether the patient had been previously hospitalized or had received antibiotic treatment. The most relevant findings were the presence of 33.8% penicillin-resistant Streptococcus pneumoniae isolates, 25% beta-lactamase-producing Haemophilus influenzae isolates, and 36.4% amoxicillin-resistant Escherichia coli isolates. All of these bacteria were fully susceptible to ceftriaxone. Nosocomial multiply-resistant bacteria, and particularly methicillin-resistant S. aureus, were found, as expected, at a higher frequency among previously hospitalized patients. However, such bacteria may be present in the community; their incidence is high in particular clinical settings, and such bacteria should be considered when one is choosing a first-line therapy for the treatment of severe infections.

References

Sep 1, 1991·Antimicrobial Agents and Chemotherapy·G A Jacoby, A A Medeiros
Nov 1, 1990·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G ArletA Philippon

❮ Previous
Next ❯

Citations

Nov 15, 2002·International Journal of Antimicrobial Agents·J A DromignyJ D Perrier Gros Claude
Oct 15, 2005·Clinical Microbiology Reviews·David L Paterson, Robert A Bonomo
May 18, 1999·Archives of Disease in Childhood·R J TomlinsonV Saha
Mar 12, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G Miflin, S E Kinsey
Oct 20, 2009·Médecine et maladies infectieuses·S ThibautUNKNOWN Microbiology laboratories of the Pays de la Loire Region
Feb 13, 2001·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D TalonJ M Estavoyer
May 22, 2016·Infectious Disease Clinics of North America·Amos AdlerDror Marchaim
Sep 24, 2016·Infectious Disease Clinics of North America·Amos AdlerDror Marchaim
May 23, 2015·Future Microbiology·Ruthy Tal JasperDror Marchaim
Aug 6, 2010·The Journal of Toxicological Sciences·Anurag PayasiAnuj Bhatnagar
Aug 1, 2021·Pharmacology Research & Perspectives·Ashagrachew TewabeGebremariam Birhanu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.